Adverum Biotechnologies Inc. is a clinical-stage gene therapy company focused on developing novel treatments for serious eye diseases. The company's mission is to develop gene therapies that have the potential to improve vision and halt the progression of debilitating eye diseases.
Adverum Biotechnologies was founded in 2006 and is headquartered in Redwood City, California. The company has developed a proprietary platform technology called VectorGraft, which is designed to deliver therapeutic genes directly to the retina to treat a range of eye diseases.
One of the key strengths of Adverum Biotechnologies is its focus on rare and underserved diseases. The company is developing gene therapies for rare genetic disorders such as Leber congenital amaurosis (LCA), which is a genetic disorder that causes severe vision loss in infants and children. Adverum Biotechnologies' gene therapy candidate for LCA is currently in Phase 2 clinical trials, and early results have shown promise in improving vision and halting disease progression.
Another key strength of Adverum Biotechnologies is its commitment to innovation and technology. The company's VectorGraft platform is designed to overcome the limitations of existing gene therapy delivery technologies by providing a more efficient and targeted approach to gene therapy. Adverum Biotechnologies is also exploring the potential of using its VectorGraft technology to develop gene therapies for other diseases beyond the eye.
Adverum Biotechnologies has also demonstrated a commitment to collaboration and partnerships. The company has established partnerships with other biotechnology companies and academic institutions to advance its research and development programs. For example, Adverum Biotechnologies has a collaboration agreement with Editas Medicine to develop gene therapies for inherited retinal diseases.
In recent years, Adverum Biotechnologies has made significant progress in advancing its gene therapy candidates through clinical trials. The company's pipeline includes gene therapies for LCA, wet age-related macular degeneration (wAMD), and diabetic macular edema (DME), all of which are serious eye diseases with limited treatment options.
Adverum Biotechnologies is a company that is dedicated to developing novel gene therapies that have the potential to improve vision and halt the progression of serious eye diseases. With a focus on innovation, collaboration, and rare and underserved diseases, Adverum Biotechnologies is well-positioned to continue to advance its pipeline and make a meaningful impact in the field of gene therapy.